The Medicare Price Negotiation: Unpacking the 71% Ozempic Discount

CMS negotiated a 71% discount on semaglutide effective January 1, 2027. Unpacking what the number means, how it was calculated, and what it does to commercial pricing.

In late 2025, the White House announced that the Centers for Medicare & Medicaid Services had negotiated a 71% discount on Ozempic and Wegovy under the Inflation Reduction Act's Medicare Drug Price Negotiation Program. The negotiated price, which becomes effective January 1, 2027, represents one of the largest single-drug negotiated reductions in Medicare history and will fundamentally reshape federal GLP-1 spending.

The negotiation applies to semaglutide — the active ingredient in both Ozempic (approved for type 2 diabetes) and Wegovy (approved for chronic weight management and cardiovascular risk reduction). Medicare Part D plans will be required to cover the drug at the negotiated Maximum Fair Price for eligible beneficiaries starting in 2027.

How the Negotiation Worked

The Inflation Reduction Act, signed into law in 2022, gave Medicare direct authority to negotiate prices on a limited number of high-spend Part D drugs. Semaglutide was selected in the second negotiation cycle based on its total Medicare Part D spending, which had grown rapidly as Medicare coverage for Ozempic expanded for type 2 diabetes and as cardiovascular-benefit coverage for Wegovy was added in 2024.

CMS and Novo Nordisk exchanged offers, counter-offers, and evidentiary submissions across 2025. The statutory framework requires CMS to consider clinical benefit, unmet medical need, budget impact, and comparative effectiveness — not just price. The final Maximum Fair Price reflects that multi-factor analysis.

What 71% Off Looks Like

The 71% figure applies to the pre-negotiation list price, not the current cash-pay price. In practice, the negotiated price puts Medicare at roughly parity with the cash-pay NovoCare commercial program. What changes for Medicare beneficiaries is coverage mechanics: Part D plans must cover it, cost-sharing follows Part D rules, and the drug flows through standard pharmacy benefit channels rather than cash-pay direct purchase.

The Coverage Expansion Question

Negotiated pricing is only useful to beneficiaries if Medicare actually covers the drug for their condition. Ozempic has been covered under Medicare Part D for type 2 diabetes for years. Wegovy's Medicare coverage expanded meaningfully in 2024 after the FDA approved a cardiovascular risk reduction indication based on the SELECT trial data.

The separate CMS BALANCE Model, announced in December 2025, is designed to further expand GLP-1 access for Medicare beneficiaries with obesity plus qualifying comorbidities. Together, the price negotiation and BALANCE Model represent the most significant federal expansion of GLP-1 coverage since the drugs became available. See our full timeline of the BALANCE Model rollout.

What the Negotiation Doesn't Cover

Tirzepatide (Zepbound, Mounjaro) was not part of the second negotiation cycle. Eli Lilly's product is newer, and the statutory framework requires a minimum period on the market before a drug is eligible for negotiation. Tirzepatide becomes eligible in a future cycle, with negotiated pricing potentially taking effect in 2028 or 2029 depending on how CMS structures the selection.

Until then, the two branded GLP-1s will operate under very different pricing regimes for Medicare beneficiaries: semaglutide at the negotiated price, tirzepatide at whatever commercial price LillyDirect and standard Part D plans have in place.

Spillover Effects on Commercial Pricing

Historically, Medicare negotiated prices have created downward pressure on commercial pricing for the same drug. Private insurers benchmark against Medicare's position in rebate negotiations, and manufacturers are reluctant to offer commercial prices that diverge too far from the government's benchmark.

For GLP-1s, the direction of pressure was already set. Novo's November 2025 cut to $349/month and Lilly's Zepbound vial pricing both preceded the negotiation announcement. The negotiation reinforces a trend that was already in motion. For more on the competitive pricing dynamics, see our 2026 Novo vs. Lilly revenue forecasts.

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, pricing data, or provider selection.